Cite
Jayaraman P, Parikh F, Newton JM, et al. TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy. Oncoimmunology. 2018;7(10):e1490853doi: 10.1080/2162402X.2018.1490853.
Jayaraman, P., Parikh, F., Newton, J. M., Hanoteau, A., Rivas, C., Krupar, R., Rajapakshe, K., Pathak, R., Kanthaswamy, K., MacLaren, C., Huang, S., Coarfa, C., Spanos, C., Edwards, D. P., Parihar, R., & Sikora, A. G. (2018). TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy. Oncoimmunology, 7(10), e1490853. https://doi.org/10.1080/2162402X.2018.1490853
Jayaraman, Padmini, et al. "TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy." Oncoimmunology vol. 7,10 (2018): e1490853. doi: https://doi.org/10.1080/2162402X.2018.1490853
Jayaraman P, Parikh F, Newton JM, Hanoteau A, Rivas C, Krupar R, Rajapakshe K, Pathak R, Kanthaswamy K, MacLaren C, Huang S, Coarfa C, Spanos C, Edwards DP, Parihar R, Sikora AG. TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy. Oncoimmunology. 2018 Jul 26;7(10):e1490853. doi: 10.1080/2162402X.2018.1490853. eCollection 2018. PMID: 30288358; PMCID: PMC6169570.
Copy
Download .nbib